Search

Your search keyword '"de Gonzalez, A. Berrington"' showing total 13 results
Start Over Author "de Gonzalez, A. Berrington" Journal cancer causes & control
13 results on '"de Gonzalez, A. Berrington"'

5. Correction to: The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems

Author

Ramin, Cody, primary, Gierach, Gretchen L., additional, Abubakar, Mustapha, additional, Veiga, Lene H. S., additional, Vo, Jacqueline B., additional, Curtis, Rochelle E., additional, Bowles, Erin J. Aiello, additional, Feigelson, Heather Spencer, additional, Buist, Diana S. M., additional, de Gonzalez, Amy Berrington, additional, and Bodelon, Clara, additional

Published
2022
Full Text
View/download PDF

9. Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts

Author

Jiao, Li, de Gonzalez, Amy Berrington, Hartge, Patricia, Pfeiffer, Ruth M., Park, Yikyung, Freedman, D. Michal, Gail, Mitchell H., Alavanja, Michael C. R., Albanes, Demetrius, Freeman, Laura E. Beane, Chow, Wong-Ho, Huang, Wen-Yi, Hayes, Richard B., Hoppin, Jane A., Ji, Bu-tian, Leitzmann, Michael F., Linet, Martha S., Meinhold, Cari L., Schairer, Catherine, Schatzkin, Arthur, Virtamo, Jarmo, Weinstein, Stephanie J., Zheng, Wei, and Stolzenberg-Solomon, Rachael Z.

Published
2010

11. The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.

Author

Ramin, Cody, Gierach, Gretchen L., Abubakar, Mustapha, Veiga, Lene H. S., Vo, Jacqueline B., Curtis, Rochelle E., Bowles, Erin Jaiello, Feigelson, Heather Spencer, Buist, Diana S. M., de Gonzalez, Amy Berrington, and Bodelon, Clara

Abstract

Purpose: Estrogen receptor (ER) + /progesterone receptor (PR) – or ER−/PR + breast cancer prognosis has not been well-described outside of clinical trials. We evaluated the relationship between ER/PR (ER + /PR−, ER−/PR + , ER + /PR + , ER−/PR−) subgroups and breast cancer-specific mortality within a general community setting in the US. Methods: A Retrospective cohort of 11,737 women diagnosed with breast cancer between 1990 and 2016 within US integrated healthcare systems (median follow-up = 7 years; 1,104 breast cancer-specific deaths) were included in this analysis. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) adjusting for site, demographic and clinicopathological characteristics, and treatment (surgery/radiotherapy, chemotherapy, endocrine therapy). Results: Breast cancer-specific mortality was higher for those with ER + /PR− (n = 1,233) compared with ER + /PR + tumors (n = 8,439) before (HR = 1.43; 95% CI = 1.17–1.75) and after treatment adjustment (HR = 1.58; 95% CI = 1.27–1.97). ER + /PR− breast cancer-specific mortality remained higher than ER + /PR + tumors when stratified by treatment received. Breast cancer-specific mortality was similar in ER–/PR + (n = 161) compared with ER + /PR + tumors. Conclusion: Our findings suggest that ER + /PR− tumors may have worse breast cancer-specific mortality than ER + /PR + tumors in a community setting. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. Correction to: The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems.

Author

Ramin, Cody, Gierach, Gretchen L., Abubakar, Mustapha, Veiga, Lene H. S., Vo, Jacqueline B., Curtis, Rochelle E., Bowles, Erin J. Aiello, Feigelson, Heather Spencer, Buist, Diana S. M., de Gonzalez, Amy Berrington, and Bodelon, Clara

Subjects
HORMONE receptor positive breast cancer, BREAST cancer treatment, CANCER-related mortality
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results